Analysis of the results of preclinical in vivo assays of IGF-1R inhibitors that supported subsequent clinical investigations showed mixed activity and protocols that poorly reflected the treatment of advanced metastatic tumors in humans.<h4>Conclusions and relevance</h4>Failed drug development in oncology incurs substantial expense. The gene discussed is IGF1R; the disease is metastatic neoplasm.